Harmony Biosciences Holdings, Inc. (HRMY)
HRMYNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$33.76
-0.0400 (-0.12%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $1.98bn
- P/E
- 11.2
- EPS, last 4 quarters
- $3.02
- Dividend yield
- –
- Day range
- –
- 52-week range
- $25.90 to $43.49
- Average volume
- –
- Previous close
- $33.80
Analysts
7 coveringBuy5 buy, 1 hold, 1 sell
Targets a year out average $47.50, +40.7% from here
Earnings
next estimate $0.9200Next report
Dec 2025
-54.8%
Mar 2026
-27.6%
Jun 2026
+32.0%
Sep 2026
-19.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $243.78m | $215.39m | $261.28m | $268.92m |
| Gross profit | $175.23m | $170.88m | $198.08m | $188.23m |
| Operating income | $38.56m | $37.29m | $89.32m | $54.20m |
| Net income | $22.49m | $32.49m | $75.43m | $48.20m |
Last four quarters: revenue $989.36m, margin 18.1%, free cash flow –
News
8 latest- HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix GrowthZacks · Nov 5, 2026
- Harmony Biosciences Holdings, Inc. Reports Q3 2026 WAKIX Net Revenue of $269 MillionFintel · Nov 4, 2026
- Harmony Biosciences (HRMY) Q3 2026 Earnings Call TranscriptThe Motley Fool · Nov 4, 2026
- Harmony Biosciences Q3 Earnings Call HighlightsMarketBeat · Nov 4, 2026
- Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings and Revenues Lag EstimatesZacks · Nov 4, 2026
- PTC Therapeutics (PTCT) Q3 Earnings and Revenues Surpass EstimatesZacks · Oct 29, 2026
- Earnings Preview: BioAge Labs, Inc. (BIOA) Q3 Earnings Expected to DeclineZacks · Oct 29, 2026
- GSK Q3 Earnings Top Mark, Stock Down on Soft Vaccines SalesZacks · Oct 28, 2026
The company
Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa, we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- harmonybiosciences.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.